Release date: 2024-08-27 17:31:04 Article From: Lucius Laos Recommended: 124
Balversa is an anti-tumor drug for FGFR mutant tumors, which is usually administered orally in clinical practice and has excellent tumor inhibition ability.
When using Balversa, the following two points should be noted:
Balversa can cause a variety of side effects, including digestive discomfort, vision problems, liver damage, and more. Patients should monitor their condition regularly seek medical attention and inform their doctor that they are taking Balversa if they feel unwell.
Balversa may interact with certain medications, affecting efficacy or increasing the risk of adverse effects. While using Balversa, patients should inform their doctor of all medications they are taking, including prescription medications, over-the-counter medications, vitamins, mineral supplements, etc., to ensure safe use.
When using Balversa, it is important to understand and comply with the precautions, and also pay attention to the adverse reactions it may cause, so that timely measures can be taken to ensure the safety of patients.
When using Balversa, patients may experience the following two main adverse effects:
Nausea, vomiting, diarrhea, and loss of appetite are common adverse effects of Balversa and may affect nutrient absorption and daily activities.
Some patients may experience eye problems such as blurred vision, dry eyes, eye pain, and even affected vision in severe cases. This may be related to the potential effects of the drug on the eye tissues, which requires close attention and prompt treatment.
While Balversa exerts a therapeutic effect, it may also cause adverse reactions. Among them, eye problems require special attention, and understanding their clinical manifestations can help early detection and intervention.
The clinical manifestations of ocular problems that may be caused by Balversa mainly include:
Patients may feel that they do not see objects clearly enough and their vision becomes blurred, which may be due to the effects of the drug on the retina or optic nerve.
Symptoms such as dry eyes, eye pain, and photophobia may be caused by drug-induced eye inflammation or irritation, which can affect the patient's daily life and work. Once these eye problems are recognized, patients should seek medical attention and inform their doctor that they are taking Balversa so that they can take appropriate measures.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: